Abstract P3-11-11: Ductal Carcinoma in Situ: Molecular and Cellular Basis of Malignant Transition

Fariba Behbod, Emily Nissen, Hong Yan, Veena Kochat, Rashna Madan, Seema A. Khan, Andrew K. Godwin, Devin C. Koestler, Mahinur Maitituoheti, Kunal RaiClinical 2025 · DOI

Abstract

Abstract Background: The goal of this study is to test whether cellular stemness drives the metastatic progression of human DCIS. DCIS is the most common type of non-invasive breast cancer and is considered a precursor to invasive ductal carcinoma (IDC). The 20-year breast cancer-specific mortality rate following a DCIS diagnosis is approximately 3.3%. The current radiation and anti-hormonal therapy have not reduced mortality associated with DCIS, which is quite intriguing. Moreover, significant racial disparities exist in mortality outcomes since Black women with DCIS compared to White women demonstrate a 7.5-fold increase in breast cancer-related mortality as well as a 12-fold risk when diagnosed before the age of 50. While the reasons for these racial disparities are not known, previous studies have suggested increased stem cell-like characteristics in breast cancer cells from women of African ancestry as compared to those with Caucasian ancestry. Additionally, studies have shown that HER2 could be a potential biomarker for DCIS, indicating future risk of regional and distant metastasis. Approach: We have developed a model referred to as the Mouse INtraDuctal (MIND) model, which mimics the non-invasive to invasive transition of human breast cancers. To generate the models, DCIS tissues were obtained from the clinics and digested into single cells followed by their intraductal injection to generate the MIND models, and a portion of the cells were subjected to single-cell transcriptomic and epigenomic analysis. Patient DCIS and DCIS with associated IDC were also subjected to spatial transcriptomics. Results: We conducted scATAC/RNA sequencing on epithelial cells from ten patients with DCIS and DCIS with associated IDC. The analysis of stemness using CytoTRAE as defined by Gulati et al., revealed that two clusters (9 & 0) had the highest stemness scores. These two clusters also exhibited high expression of FOXA1, and a strong correlation was observed between stemness score and FOXA1 expression, particularly in HER2-3+ DCIS/IDC samples compared to HER2-3+ pure DCIS, luminal or TNBC. We also found that the open chromatin regions in the stemness clusters were highly enriched for FOXA1 binding motifs, particularly in HER2-3+ DCIS/IDC samples. Additionally, single-cell RNA sequencing was performed on 60,000 cells from 17 samples of DCIS, including 9 that progressed in the MIND models and 8 that remained non-invasive. The stemness scores, determined using CytoTRACE were significantly higher in progressed DCIS cells compared to non-progressed cells. There was also a notable correlation between the expression of FOXA1 and the stemness scores. Additionally, we performed spatial transcriptomics (10x Genomics-Xenium) on sixteen patient DCIS samples, including eleven HER2-3+ (five pure DCIS and six DCIS/IDC) and five HER2-negative (three pure DCIS and two DCIS/IDC). As expected, the CytoTRACE analysis indicated that luminal HR+ epithelial cells in DCIS/IDC HER2-3+ samples exhibited the highest overall level of stemness. FOXA1 was identified as one of the top 10 genes associated with stemness. Ligand receptor (LR) interaction analysis identified the highest dissimilar LR pairs was CEACAM6-EGFR. CEACAM6 was upregulated on luminal HR+ cells with the highest stemness scores and interacted with EGFR expressed by luminal secretory, B cells, T cells, myeloid, mast cells vascular and lymphatic cells. High CEACAM6 expression is associated with poor survival and metastasis in several cancer types, including pancreatic cancers and breast cancers. Conclusion: The presence of a spatial niche containing stem-like cells with increased epigenetic activity of FOXA1 may drive the invasive and metastatic progression in DCIS. We suggest that targeting the activity of FOXA1 can inhibit the function of these stem-like cells and prevent metastatic or invasive progression of human DCIS. Additionally, CEACAM6-EGFR may facilitate communication between epithelial stem cells and their stromal niches, promoting progression. Citation Format: Fariba Behbod, Emily Nissen, Yan Hong, Veena Kochat, Rashna Madan, Seema Khan, Andrew K. Godwin, Devin C. Koestler, Mahinur Maitituoheti, Kunal Rai. Ductal Carcinoma in Situ: Molecular and Cellular Basis of Malignant Transition [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P3-11-11.
BibTeX
@inproceedings{behbod2025abstract,
  author = {Fariba Behbod and Emily Nissen and Hong Yan and Veena Kochat and Rashna Madan and Seema A. Khan and Andrew K. Godwin and Devin C. Koestler and Mahinur Maitituoheti and Kunal Rai},
  title = {{Abstract P3-11-11: Ductal Carcinoma in Situ: Molecular and Cellular Basis of Malignant Transition}},
  booktitle = {Clinical},
  year = {2025},
  doi = {10.1158/1557-3265.sabcs24-p3-11-11},
}

Loading related content...

Figure